Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Persica Pharmaceuticals Ltd. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed between 2 distinct examiners, providing the company with multiple points of contact within the patent office. Despite the involvement of different examiners, all current activity is focused within 1 distinct art unit, which suggests a specialized technical domain for the company's pharmaceutical applications.
The busiest examiner for the portfolio is LEE, SIN J, who is overseeing 1 busiest examiner pending action. With 2 pending office actions and 2 distinct examiners, the workload is evenly divided, meaning each examiner is responsible for a single active matter. This distribution in the Biotechnology & Pharmaceuticals sector allows the company to receive feedback from different perspectives while remaining within the same technical group.
The presence of multiple examiners for these active matters requires careful coordination to maintain a consistent prosecution strategy. While LEE, SIN J handles 1 busiest examiner pending action, the other matter is being reviewed by a different official, which may lead to different examination outcomes. Practitioners must monitor these actions closely to ensure the company's overall goals in the 1 distinct art unit are met.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, SIN J | 1 | 68.8% | +25.1% |
| SASAN, ARADHANA | 1 | 64.5% | +26.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18700578 | LOW BACK PAIN TREATMENT | SASAN, ARADHANA | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18700578 | LOW BACK PAIN TREATMENT | SASAN, ARADHANA | 55d |
| 18932807 | ANTIBIOTIC FORMULATIONS FOR LOWER BACK PAIN | LEE, SIN J | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18932807 | ANTIBIOTIC FORMULATIONS FOR LOWER BACK PAIN | LEE, SIN J | — | §103§112DP | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18700578 | LOW BACK PAIN TREATMENT | SASAN, ARADHANA | 1615 | §102§103§112Other | Non-Final OA | 55d | Pending | Apr 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial